Stephens Reiterates “Overweight” Rating for Certara (NASDAQ:CERT)

Certara (NASDAQ:CERT)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Stephens in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $17.00 target price on the stock. Stephens’ target price would suggest a potential upside of 37.71% from the company’s previous close.

A number of other brokerages have also weighed in on CERT. Barclays decreased their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. TD Cowen initiated coverage on Certara in a research report on Thursday. They issued a “buy” rating and a $16.00 target price on the stock. Finally, Robert W. Baird dropped their price target on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Certara currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.64.

Certara Price Performance

Shares of NASDAQ CERT opened at $12.35 on Thursday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The firm has a market cap of $1.99 billion, a PE ratio of -61.95, a PEG ratio of 9.29 and a beta of 1.57. Certara has a one year low of $9.41 and a one year high of $19.87. The firm has a fifty day moving average of $12.39 and a 200 day moving average of $11.63.

Hedge Funds Weigh In On Certara

A number of institutional investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. increased its stake in shares of Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after acquiring an additional 822 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Certara by 3.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company’s stock worth $253,000 after purchasing an additional 823 shares during the last quarter. Wells Fargo & Company MN raised its stake in Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after purchasing an additional 1,047 shares during the period. Nicolet Advisory Services LLC raised its stake in Certara by 6.6% during the third quarter. Nicolet Advisory Services LLC now owns 24,831 shares of the company’s stock worth $273,000 after purchasing an additional 1,531 shares during the period. Finally, KBC Group NV boosted its holdings in Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after purchasing an additional 1,584 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.